The Ontario Colposcopy Community of Practice Resources Hub

Guideline-based clinical tools for best practice delivery of colposcopy services, including pathways, and referral and discharge templates.

• PDF: Ontario Cervical Screening Program: Guide to colposcopy
• Letter template: Declined referral

Discharge letter templates – from a colposcopist to a primary care provider

• Letter template: Discharge letter (version 1 – patient discharged from colposcopy)
• Letter template: Discharge letter (version 2 – patient discharged from colposcopy)
• Letter template: Discharge letter (patient has had a hysterectomy)
• Letter template: Discharge letter (patient has met the screening cessation criteria)

Discharge letter templates – from a colposcopist to a patient

• Letter template: Discharge letter (patient discharged from colposcopy)
• Letter template: Discharge letter (patient has had a hysterectomy)
• Letter template: Discharge letter (patient has met the screening cessation criteria)

A framework for optimal delivery of consistent high-quality colposcopy services in Ontario.

• Colposcopy training, qualification and maintenance of competence
• Practice setting requirements
• Operational practices
• Quality indicators and outcomes

• How to access the physician-level cervical screening and colposcopy quality reports
• Key dates and educational activities leading up to the launch of HPV testing implementation in the Ontario Cervical Screening Program (OCSP)
• The new OCSP post-colposcopy discharge screening intervals
• Screening and colposcopy considerations in the OCSP
• Key practice changes once HPV testing is implemented in the OCSP

• How to access the physician-level cervical screening and colposcopy quality reports
• What to expect leading up to the launch of human papillomavirus (HPV) testing implementation
• The new future state colposcopy pathways

• How to access the physician-level cervical screening and colposcopy quality reports
• What to expect leading up to the launch of HPV testing implementation
• The new future state cervical screening recommendations and vaginal vault testing guidance
• A high-level overview of the future state colposcopy recommendations

• What to expect leading up to the launch of human papillomavirus (HPV) testing implementation
• Trends in cervical screening and colposcopy services in Ontario
• How to access the physician-level cervical screening and colposcopy quality reports
• Management of adenocarcinoma in situ (AIS) histology according to margin status

• Trends in cervical screening and colposcopy services in Ontario
• How to manage people with persistent post-treatment low-grade cytology test results
• How to access and use the new physician-level cervical screening and colposcopy quality reports
• Appropriate next step for when microinvasive cervical cancer is identified on the loop electrosurgical excision procedure (LEEP) specimen

• Trends in cervical screening and colposcopy services in Ontario
• The associated risks of HSIL histology for people with HPV-positive and low-grade cytology results
• What to expect from the future colposcopy quality physician-level reports and how to ensure colposcopists can benefit from quality reporting activities
• Post-treatment management for AIS histology

• The impact of the COVID-19 pandemic on cervical screening and colposcopy services in Ontario 
• Risk-based recommendations for management of patients with atypical glandular cells, favour neoplasia (AGC-N)
• What to expect for the 2022 quality reports and how to ensure colposcopists are able to benefit from quality reporting activities
• Risk-based recommendations for management of patients with adenocarcinoma in-situ (AIS) and positive margins on loop electrosurgical excision procedure (LEEP)

• The impact of the COVID-19 pandemic on cervical screening and colposcopy services in Ontario 
• Risk-based recommendations for discharge from colposcopy for treated and untreated patients 
• What to communicate to primary care providers when discharging people from colposcopy
• The impact of endocervical gland extension on persistence/ recurrence of cervical dysplasia
• What to expect for the 2022 quality reports and how to ensure they are able to benefit from quality reporting activities

• Cervical screening considerations for transgender patients, including appropriate terminology and barriers to care
• The impact of the COVID-19 pandemic on cervical screening and colposcopy services in Ontario
• How to interpret cervical screening and colposcopy quality reports to support quality improvement activities

Webinar Recording: Implementation of Human papillomavirus (HPV) Test in Australia (presentation only)

Webinar Recording: Implementation of HPV Test in Australia (question and answer session)

Slides and full recording from the Spring 2021 CoP session on June 18, 2021:

• The impact of the COVID-19 pandemic on cervical screening and colposcopy services in Ontario
• Risk-based assessment for discharge from colposcopy for treated and untreated patients
• What to communicate to primary care providers when discharging people from colposcopy
• Appropriate use of HPV testing according to current OCSP recommendations when accessible

Slides and full recording from the Fall 2020 CoP session on November 26, 2020:

• Considerations for cervical screening and colposcopy care amidst the COVID-19 pandemic
• Risk assessment of patients with AIS cytology results and implications for colposcopy
• Appropriate use of HPV testing within the current screening setting

Slides and full recording from the Spring 2020 CoP session on June 29, 2020:

• Considerations for cervical screening and colposcopy care in LGBTQ populations
• Risk assessment of patients with high-grade cytology results and implications for screening and colposcopy
• Appropriate follow-up of patients post-colposcopy

Slides and full recording from the Fall 2019 CoP session on November 22, 2019:

• Mature women
• HPV vaccination
• Post-hysterectomy follow-up

Slides and full recording from the Spring 2019 CoP session on May 31st, 2019:

• Colposcopic images
• AIS management
• Conservative management

Slides and full recording from the Fall 2018 CoP session on November 22nd, 2018:

• LSIL + LEEP
• Immunocompromised
• Vaccinated cohort

Slides and full recording from the Spring 2018 CoP session on May 24th, 2018:

• HPV status
• HSIL in women <25 years
• Mature women

Slides and full recording from the Fall 2017 CoP session on November 17th, 2017:

• Patient with IUS
• Terminology

Slides and full recording from the Spring 2017 CoP session on June 2nd, 2017:

• ASCUS
• HSIL